Works matching IS 2160763X AND DT 2020 AND VI 9 AND IP 1

Results: 14

Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 32, doi. 10.1002/cpdd.755

By:

Anderson, Kacey;
Xin, Yan;
Zheng, Hao;
Yun, Chohee;
Kwan, Ellen;
Qin, Ann;
Namour, Florence;
Kearney, Brian P.;
Mathias, Anita

Publication type:

Article

Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug Development.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 6, doi. 10.1002/cpdd.744

By:

Tanese, Keiji;
Yamori, Takao

Publication type:

Article

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 11, doi. 10.1002/cpdd.741

By:

Miyoshi, So;
Krishnaswami, Sriram;
Toyoizumi, Shigeyuki;
Nakamura, Hiroyuki;
Zwillich, Samuel H.

Publication type:

Article

Evaluation of the Pharmacokinetic Interaction Between the Voltage‐ and Use‐Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 62, doi. 10.1002/cpdd.739

By:

Dunbar, Joi;
Versavel, Mark;
Zhao, Yuan;
Tate, Simon;
Morisset, Valerie;
Giblin, Gerard M. P.;
Palmer, Joanne;
Tidemann‐Miller, Beth;
Naik, Himanshu

Publication type:

Article

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 130, doi. 10.1002/cpdd.732

By:

Borin, Marie T.;
Barnes, Chris N.;
Darpo, Borje;
Pendyala, Srikanth;
Xue, Hongqi;
Bourdet, David L.

Publication type:

Article

Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 74, doi. 10.1002/cpdd.730

By:

Khedkar, Anand;
Lebovitz, Harold;
Fleming, Alexander;
Cherrington, Alan;
Jose, Vinu;
Athalye, Sandeep N.;
Vishweswaramurthy, Ashwini

Publication type:

Article

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 50, doi. 10.1002/cpdd.703

By:

Dawra, Vikas Kumar;
Liang, Yali;
Wei, Hua;
Pelletier, Kathleen;
Shi, Haihong;
Hickman, Anne;
Bass, Almasa;
Terra, Steven G.;
Zhou, Susan;
Krishna, Rajesh;
Sahasrabudhe, Vaishali

Publication type:

Article

First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 115, doi. 10.1002/cpdd.700

By:

Fox, Jonathan C.;
Hellawell, Jennifer L.;
Rao, Satish;
O'Reilly, Terry;
Lumpkin, Rick;
Jernelius, Jesper;
Gretler, Daniel;
Sinha, Uma

Publication type:

Article

Effects of Differential Food Patterns on the Pharmacokinetics of Enteric‐Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 41, doi. 10.1002/cpdd.696

By:

Zhang, Su‐hua;
Li, Yao;
Wei, Shan‐shan;
Guo, Lin;
Huang, Xiao‐mei;
Chen, Ying;
Wu, Xiang‐xin;
Cai, Hua‐lin;
Zhang, Bi‐kui

Publication type:

Article

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 21, doi. 10.1002/cpdd.695

By:

Carrothers, Timothy J.;
Chittenden, Jason T.;
Critchley, Ian

Publication type:

Article

Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice‐Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single‐Blind Randomized Study.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 87, doi. 10.1002/cpdd.687

By:

Kumagai, Yuji;
Ose, Atsushi;
Tanaka, Kosuke;
Sugimoto, Toshitsugu

Publication type:

Article

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 97, doi. 10.1002/cpdd.686

By:

Li, Yinhua;
Mu, Yuting;
Shi, Haihong;
Liang, Yali;
Liu, Zeyuan;
Matschke, Kyle;
Hickman, Anne;
Krishna, Rajesh;
Sahasrabudhe, Vaishali

Publication type:

Article

Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 107, doi. 10.1002/cpdd.685

By:

Sanchez, Rosa I.;
Yee, Ka Lai;
Fan, Li;
Cislak, Dawn;
Martell, Maureen;
Jordan, Heather R.;
Iwamoto, Marian;
Khalilieh, Sauzanne

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 1, doi. 10.1002/cpdd.675
Publication type:: Article